精神分裂症(面向对象编程)
疾病
小RNA
生物信息学
机制(生物学)
神经科学
医学
生物
基因
精神科
遗传学
病理
哲学
认识论
作者
Sumel Ashique,Radheshyam Pal,Anas Islam,Himanshu Sharma,Subhajit Mandal,Sanjesh Kumar,Mansi Singh,Samy Selim,Soad K. Al Jaouni,Amisha S. Raikar,Lavanya Lakshminarayana,B. Sharma,Rashmi Pathak
出处
期刊:Current Protein & Peptide Science
[Bentham Science Publishers]
日期:2025-04-14
卷期号:26
标识
DOI:10.2174/0113892037362309250319035758
摘要
Abstract: Schizophrenia is now diagnosed mostly based on symptoms and physical signs rather than the patient's pathological and physiological markers. While oncologists once felt satisfied when their patients experienced a long remission, today, they are leading research into innovative treatments with molecularly targeted drugs, as well as strategies to enhance diagnostic accuracy and alleviate symptoms as the disease advances.Because biomarkers reflect an organism's physiological, physical, and biochemical state, they are very beneficial and have a wide range of real-- world uses. The identification of blood biomarkers may open up new avenues for studying schizophrenia. MicroRNAs (miRNAs) may serve as diagnostic indicators for schizophrenia as their abnormal expression has recently been linked to the disease's pathophysiology. The precise etiological process of schizophrenia remains largely unknown despite the general agreement that developmental and genetic factors play a critical role in the pathophysiology of the disorder. miRNAs have gained recognition as an essential post-transcriptional regulator in the regulation of gene expression in recent decades. The importance of miRNAs for brain development and neuroplasticity is well established.
科研通智能强力驱动
Strongly Powered by AbleSci AI